Sarepta says the age limit in the indication could encourage swifter insurance coverage of the newly approved gene therapy for Duchenne muscular dystrophy so potential patients don't age out of the treatment window before they would be eligible for reimbursement.

Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Manufacturers will face the “biggest PBM ever” in price negotiations for pharmacy benefit drugs as a result of the collaboration between the two pharmacy benefit managers.